Plying Proteomics Skills for Premium Jobs

A 2001 surge in proteomics investment has generated record revenues, seeding a burgeoning job market and a flowering of training courses and research resources. Proteomics revenues grew 41.9% from $963 million to $1.37 billion (US), in 2001, according to Frost & Sullivan, a San Antonio, Texas-based investment firm. Most of the revenues are from sales of laboratory instruments and supplies, now leaving these fully equipped labs needing to hire staff to use the tools. "We have all this wonderful e

Written byHal Cohen
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

According to Kruip, Aventis seeks people with skills in mass spectrometry and protein and peptide chromatographic separation, but as proteomics continues to evolve, so does the definition of a qualified worker. "Right now there is no such thing as a proteomicist," says David Jensen, scientific recruiter of Search Masters International, Downer's Grove, IL. Jensen and Kruip describe the ideal candidate as one who blends an ability to work with specialized lab equipment with a working knowledge of X-ray crystallography, protein chemistry, and computational chemistry. "[But] it can't be expected for someone to have been trained exclusively in proteomics," Jensen observes.

Some fledgling scientists are jumping ahead by acquiring specific proteomics skills on their own. "I just wanted to expand the NMR [nuclear magnetic resonance] knowledge I had for the structural genomics/proteomics approach," says Daniel Monleon, a postdoc trainee at the Rutgers University center of advanced biotechnology in Piscataway, NJ.

Monleon ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies